Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets in vitro

1 Enprostil is composed, in approximately equal proportions, of 4 allenic isomers which are prostanoids structurally related to prostaglandin E2 (PGE2). The isomers are denoted as RS‐86505‐007, RS‐86812‐007 which are in the ‘natural’ R and S configuration (with respect to PGE2) and RS‐86505‐008 and RS‐86812‐008 which are in the ‘unnatural’ R and S configuration. In the present study we have characterized their activity at prostanoid receptors, in vitro. 2 Enprostil acted as a highly potent (‐log EC50 = 8.30 ± 0.08; mean ± s.e.mean, n = 6) EP3 receptor agonist in the guinea‐pig vas deferens, although no activity was observed at guinea‐pig tracheal EP2 receptors at concentrations up to and including 10 μm. Attempts to study the action of enprostil at EP1 receptors were complicated by a general increase in the spontaneous activity of the guinea‐pig isolated ileum. This response was stereospecific (i.e. observed, with the ‘natural’ R and S isomers only) and was not mediated through EP1, FP or TP receptors. 3 Enprostil also exhibited a potent agonist effect at FP and TP receptors in the rat colon and guinea‐pig aorta (‐log EC50 values = 7.34 ± 0.11 and 6.54 ± 0.07, mean ± s.e.mean, n = 4–8 respectively). No activity at concentrations up to and including 10 μm was observed at DP or IP receptors in the guinea‐pig platelet mediating inhibition of ADP‐induced aggregation. 4 A similar profile was observed with the ‘natural’ R and S allenic isomers of enprostil (RS‐86505‐007 and RS‐86812‐007, respectively); RS‐86505‐007 was between 4 and 10 fold more potent than the racemic enprostil. The ‘unnatural’ allenic R and S isomers of enprostil were much less potent than enprostil, with the latter being virtually inactive. 5 Enprostil and the ‘natural’ R and S isomers, therefore, were EP3, FP and TP agonists, being most potent at the EP3 receptor. The preferred configurations for these receptors appears to be the R, and to a lesser extent the S, form of the natural allenic isomer. The effect of enprostil at EP1 receptors was not characterized in view of the presence of excitatory EP3 receptors in the guinea‐pig ileum. These data were in accordance with the pharmacological activity of enprostil, including inhibition of gastric acid secretion (possibly EP3) and diaorrhea (possibly TP).

[1]  R. Eglen,et al.  RS‐61756‐007: a potent and selective thromboxane receptor (TP) agonist , 1989, The Journal of pharmacy and pharmacology.

[2]  A. Robertson,et al.  The classification of prostaglandin DP‐receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist , 1989, British journal of pharmacology.

[3]  M. Wasserman,et al.  Effects of putative thromboxane receptor agonists and antagonists on rat small intestinal ion transport. , 1988, Journal of Pharmacology and Experimental Therapeutics.

[4]  R. Eglen,et al.  The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets , 1988, British journal of pharmacology.

[5]  M. Beinborn,et al.  Enrichment and characterization of specific [3H]PGE2 binding sites in the porcine gastric mucosa. , 1988, European journal of pharmacology.

[6]  J. Esplugues,et al.  Close-arterial administration of the thromboxane mimetic U-46619 induces damage to the rat gastric mucosa. , 1988, Prostaglandins.

[7]  K. Bunce,et al.  Mechanism of stimulation of colonic secretion in the rat by the prostanoid enprostil , 1988 .

[8]  J. J. Reeves,et al.  Thromboxane receptors can modulate gastric acid secretion in the rat. , 1987, Prostaglandins.

[9]  J. Rask-Madsen,et al.  Enprostil and ranitidine in prevention of duodenal ulcer relapse: one year double blind comparative trial. , 1987, British medical journal.

[10]  R. A. Coleman Methods in prostanoid receptor classification , 1987 .

[11]  Á. Guzmán,et al.  Synthesis and gastric antisecretory properties of allenic 16-phenoxy-omega-tetranor prostaglandin E analogs. , 1987, Prostaglandins.

[12]  P. Collins,et al.  Chapter 19 Agents for the Treatment of Peptic Ulcer Disease , 1987 .

[13]  A. Roszkowski,et al.  Gastric antisecretory and antiulcer properties of enprostil, (+/-)-11 alpha, 15 alpha-dihydroxy-16-phenoxy-17,18,19,20-tetranor-9-oxoprosta- 4,5,13(t)-trienoic acid methyl ester. , 1986, Journal of Pharmacology and Experimental Therapeutics.

[14]  G. Crean,et al.  Effect of a single oral dose of enprostil on gastric secretion and gastrin release. Studies in healthy volunteers and patients with pernicious anemia. , 1986, American Journal of Medicine.

[15]  J. Isenberg,et al.  Enprostil, a synthetic prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcer. , 1986, The American journal of medicine.

[16]  R. Álvarez,et al.  Prostanoid inhibition of canine parietal cells. , 1986, The American journal of medicine.

[17]  B. Whittle,et al.  Prostaglandin D2 interacts at thromboxane receptor‐sites on guinea‐pig platelets , 1986, British journal of pharmacology.

[18]  L. Waterbury,et al.  Gastric mucosal binding studies with enprostil: a potent anti-ulcer prostaglandin. , 1986, Prostaglandins.

[19]  R. Robertson Characterization and regulation of prostaglandin and leukotriene receptors: an overview. , 1986, Prostaglandins.

[20]  Yang Dong,et al.  Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues , 1986, British journal of pharmacology.

[21]  J. J. Reeves,et al.  Effects of indomethacin, piroxicam and selected prostanoids on gastric acid secretion by the rat isolated gastric mucosa , 1985, British journal of pharmacology.

[22]  R. Gorman,et al.  Cytoprotective and antisecretory properties of a non-diarrheogenic and non-uterotonic prostacyclin analog: U-68,215. , 1985, Prostaglandins.

[23]  M. Beinborn,et al.  Binding of 3H-iloprost to rat gastric mucosa: a pitfall in performing radioligand binding assays. , 1985, Research communications in chemical pathology and pharmacology.

[24]  B. Whittle,et al.  Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea‐pig platelets , 1985, British journal of pharmacology.

[25]  D. Wilson,et al.  Effects of prostaglandin E2, 16,16-dimethyl prostaglandin E2 and a prostaglandin endoperoxide analogue (U-46619) on gastric secretory volume, [H+] and mucus synthesis and secretion in the rat. , 1984, Prostaglandins.

[26]  R. A. Coleman,et al.  Studies on the characterisation of prostanoid receptors: a proposed classification. , 1982, Prostaglandins.

[27]  R. A. Coleman,et al.  COMPARISON OF THE ACTIONS OF U‐46619, A PROSTAGLANDIN H2‐ANALOGUE, WITH THOSE OF PROSTAGLANDIN H2 AND THROMBOXANE A2 ON SOME ISOLATED SMOOTH MUSCLE PREPARATIONS , 1981, British journal of pharmacology.

[28]  J. Emmerson,et al.  The zig‐zag tracheal strip , 1979, The Journal of pharmacy and pharmacology.

[29]  P. Hedqvist,et al.  Prostaglandin-induced neurotransmission failure in the field-stimulated, isolated vas deferens. , 1972, Neuropharmacology.

[30]  R. Furchgott The Classification of Adrenoceptors (Adrenergic Receptors). An Evaluation from the Standpoint of Receptor Theory , 1972 .

[31]  R. B. Parker,et al.  Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists. , 1971, The Journal of pharmacology and experimental therapeutics.